FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1829342801> ?p ?o ?g. }

• W1829342801 endingPage "756" @default.
• W1829342801 startingPage "756" @default.
• W1829342801 abstract "Neuromyelitis optica (NMO) is characterized by disabling relapses of optic neuritis and myelitis and the presence of aquaporin 4 antibodies (AQP4-abs). Interleukin 6, which is significantly elevated in serum and cerebrospinal fluid of patients with NMO, induces AQP4-ab production by plasmablasts and represents a novel therapeutic target.To evaluate the long-term safety and efficacy of tocilizumab, a humanized antibody targeting the interleukin 6 receptor, in NMO and NMO spectrum disorder.Retrospective observational study with 10 to 51 months of follow-up between December 2010 and February 2015, in neurology departments at tertiary referral centers. Participants were 8 female patients of white race/ethnicity with highly active AQP4-ab-seropositive NMO (n = 6) and NMO spectrum disorder (n = 2) whose disease had been resistant to previous medications, including B-cell depletion, and who switched to tocilizumab (6-8 mg/kg of body weight per dose).Annualized relapse rate, Expanded Disability Status Scale score, spinal cord and brain magnetic resonance imaging, AQP4-ab titers, pain levels (numerical rating scale), and adverse effects.Patients were followed up for a mean (SD) of 30.9 (15.9) months after switching to tocilizumab. Two of eight patients received add-on therapy with monthly corticosteroid pulses (temporary) or azathioprine, respectively. During tocilizumab treatment, the median annualized relapse rate significantly decreased from 4.0 (interquartile range, 3.0-5.0) in the year before tocilizumab therapy to 0.4 (interquartile range, 0.0-0.8) (P = .008), and the median Expanded Disability Status Scale score significantly decreased from 7.3 (interquartile range, 5.4-8.4) to 5.5 (interquartile range, 2.6-6.5) (P = .03). Active magnetic resonance imaging lesions were seen in 6 of 8 patients at tocilizumab initiation and in 1 of 8 patients at the last magnetic resonance imaging. Three patients remained relapse free during tocilizumab treatment. In 5 patients, a total of 8 relapses occurred, 4 within the first 2½ months of therapy. Five attacks were associated with delayed tocilizumab administration (≥40 days), and 6 attacks were associated with reduced tocilizumab dosage (6 vs 8 mg/kg). The AQP4-ab titers (P = .02) and pain levels (P = .02) dropped significantly during tocilizumab treatment. Adverse effects included moderate cholesterol elevation in 6 of 8 patients, infections in 4 of 8 patients, and deep venous thrombosis and neutropenia in one patient each.Prolonged tocilizumab therapy may be safe and effective from early treatment phases onward for otherwise therapy-resistant highly active NMO and NMO spectrum disorder. Relapse patterns indicate that adherence to a regular therapeutic regimen with monthly infusions of tocilizumab (8 mg/kg) may increase efficacy." @default.
• W1829342801 created "2016-06-24" @default.
• W1829342801 creator A5008016806 @default.
• W1829342801 creator A5012009103 @default.
• W1829342801 creator A5031075667 @default.
• W1829342801 creator A5037084636 @default.
• W1829342801 creator A5043996334 @default.
• W1829342801 creator A5045137085 @default.
• W1829342801 creator A5046121285 @default.
• W1829342801 creator A5046354840 @default.
• W1829342801 creator A5062220148 @default.
• W1829342801 creator A5063615479 @default.
• W1829342801 creator A5068835941 @default.
• W1829342801 creator A5070191933 @default.
• W1829342801 creator A5082742479 @default.
• W1829342801 creator A5086459629 @default.
• W1829342801 creator A5087811944 @default.
• W1829342801 date "2015-07-01" @default.
• W1829342801 modified "2023-10-11" @default.
• W1829342801 title "Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder" @default.
• W1829342801 cites W1921385723 @default.
• W1829342801 cites W1971209049 @default.
• W1829342801 cites W1974922509 @default.
• W1829342801 cites W1976554229 @default.
• W1829342801 cites W1991019975 @default.
• W1829342801 cites W2007147688 @default.
• W1829342801 cites W2016845148 @default.
• W1829342801 cites W2018439132 @default.
• W1829342801 cites W2024060703 @default.
• W1829342801 cites W2029600633 @default.
• W1829342801 cites W2038941725 @default.
• W1829342801 cites W2041230047 @default.
• W1829342801 cites W2046340040 @default.
• W1829342801 cites W2047316467 @default.
• W1829342801 cites W2050098695 @default.
• W1829342801 cites W2070665570 @default.
• W1829342801 cites W2075284457 @default.
• W1829342801 cites W2076868088 @default.
• W1829342801 cites W2077427574 @default.
• W1829342801 cites W2079409038 @default.
• W1829342801 cites W2091934359 @default.
• W1829342801 cites W2096069651 @default.
• W1829342801 cites W2100093402 @default.
• W1829342801 cites W2107058921 @default.
• W1829342801 cites W2107941546 @default.
• W1829342801 cites W2112165124 @default.
• W1829342801 cites W2114414511 @default.
• W1829342801 cites W2125096061 @default.
• W1829342801 cites W2129933277 @default.
• W1829342801 cites W2135249078 @default.
• W1829342801 cites W2136132690 @default.
• W1829342801 cites W2144469764 @default.
• W1829342801 cites W2147750230 @default.
• W1829342801 cites W2150952126 @default.
• W1829342801 cites W2329280874 @default.
• W1829342801 cites W2395000481 @default.
• W1829342801 doi "https://doi.org/10.1001/jamaneurol.2015.0533" @default.
• W1829342801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25985228" @default.
• W1829342801 hasPublicationYear "2015" @default.
• W1829342801 type Work @default.
• W1829342801 sameAs 1829342801 @default.
• W1829342801 citedByCount "188" @default.
• W1829342801 countsByYear W18293428012015 @default.
• W1829342801 countsByYear W18293428012016 @default.
• W1829342801 countsByYear W18293428012017 @default.
• W1829342801 countsByYear W18293428012018 @default.
• W1829342801 countsByYear W18293428012019 @default.
• W1829342801 countsByYear W18293428012020 @default.
• W1829342801 countsByYear W18293428012021 @default.
• W1829342801 countsByYear W18293428012022 @default.
• W1829342801 countsByYear W18293428012023 @default.
• W1829342801 crossrefType "journal-article" @default.
• W1829342801 hasAuthorship W1829342801A5008016806 @default.
• W1829342801 hasAuthorship W1829342801A5012009103 @default.
• W1829342801 hasAuthorship W1829342801A5031075667 @default.
• W1829342801 hasAuthorship W1829342801A5037084636 @default.
• W1829342801 hasAuthorship W1829342801A5043996334 @default.
• W1829342801 hasAuthorship W1829342801A5045137085 @default.
• W1829342801 hasAuthorship W1829342801A5046121285 @default.
• W1829342801 hasAuthorship W1829342801A5046354840 @default.
• W1829342801 hasAuthorship W1829342801A5062220148 @default.
• W1829342801 hasAuthorship W1829342801A5063615479 @default.
• W1829342801 hasAuthorship W1829342801A5068835941 @default.
• W1829342801 hasAuthorship W1829342801A5070191933 @default.
• W1829342801 hasAuthorship W1829342801A5082742479 @default.
• W1829342801 hasAuthorship W1829342801A5086459629 @default.
• W1829342801 hasAuthorship W1829342801A5087811944 @default.
• W1829342801 hasConcept C119060515 @default.
• W1829342801 hasConcept C126322002 @default.
• W1829342801 hasConcept C203014093 @default.
• W1829342801 hasConcept C2776760755 @default.
• W1829342801 hasConcept C2777178219 @default.
• W1829342801 hasConcept C2779134260 @default.
• W1829342801 hasConcept C2780640218 @default.
• W1829342801 hasConcept C2780892749 @default.
• W1829342801 hasConcept C2781137167 @default.
• W1829342801 hasConcept C71924100 @default.
• W1829342801 hasConcept C90924648 @default.

• next